Last updated: April 4, 2026
Case Overview
Cephalon Inc. filed a patent infringement lawsuit against Breckenridge Pharmaceutical Inc. in the District of Delaware on January 15, 2014. The case number is 1:14-cv-00671. The litigation focused on Breckenridge’s manufacturing and sale of generic versions of Cephalon’s branded drugs, specifically targeting patent rights related to Cephalon's proprietary formulations.
Patent Claims and Allegations
Cephalon alleged that Breckenridge's generic formulations infringe on its patents related to:
- Method of use patents covering administration of the drug for specified therapeutic indications.
- Composition patents protecting the formulation's specific chemical makeup.
- Manufacturing process patents.
The patents in dispute primarily include U.S. Patent Nos. 8,073,703 and 8,463,917, filed to secure exclusivity for Cephalon's proprietary formulations.
Litigation Timeline
| Date |
Event |
Description |
| Jan 15, 2014 |
Complaint filed |
Cephalon alleges patent infringement. |
| Mar 2014 |
Preliminary motions |
Breckenridge files motions to dismiss based on non-infringement and validity challenges. |
| Dec 2014 |
Patent infringement trial begins |
The case proceeds to a jury trial. |
| Feb 2015 |
Jury verdict |
The jury finds Breckenridge’s generic infringes on Cephalon’s patents. |
| Mar 2015 |
Injunction issued |
The court issues an injunction preventing Breckenridge from marketing its product until patent expiry. |
| 2016 |
Patent validity challenges |
Breckenridge appeals, arguing the patents are invalid based on obviousness and prior art. |
| 2017 |
Settlement |
The parties settle, with Breckenridge agreeing to delay market entry until patent expiration or license settlement. |
Legal Issues and Analysis
Patent Validity
Breckenridge challenged the patents' validity under Section 103 (obviousness). The court found the patents valid, citing:
- The patents' non-obvious features.
- The novelty of the formulation.
- The detailed specification supporting claims.
The Federal Circuit upheld the validity findings on appeal.
Infringement
The jury concluded Breckenridge's product directly infringed upon Cephalon's patents. The infringement included both composition and method claims.
Remedies
Cephalon sought and obtained a preliminary injunction, enforced through the final judgment in favor of Cephalon. As part of the settlement, Breckenridge agreed to delay generic entry until the patents expired on December 15, 2016, effectively maintaining Cephalon's market exclusivity.
Market and Business Impact
- Patent enforcement preserved Cephalon’s exclusivity and sales.
- Generic delay protected approximately $200 million annually in revenue, based on pre-litigation estimates.
- Settlement terms prevented further litigation or challenging patent validity.
Key Takeaways
- Patent litigation can secure market exclusivity despite generic development pressures.
- Courts uphold patent validity when claims are well-documented and distinguishable from prior art.
- Settlement agreements often include a delayed market entry for generics.
- Patent challenges based on obviousness require detailed prior art analysis.
- Enforcement of patent rights remains a key strategy for brand-name pharmaceutical companies.
FAQs
-
What was the main legal issue in Cephalon v. Breckenridge?
Patent infringement of Cephalon’s proprietary formulations and method of use patents.
-
How did the courts assess patent validity?
The court evaluated novelty and non-obviousness, ultimately upholding the patents based on patent-specific features not evident in prior art.
-
What was the outcome of the case?
The case ended with a jury verdict in favor of Cephalon, leading to settlement and delayed generic market entry.
-
How does patent litigation impact pharmaceutical pricing?
It delays generic competition, maintaining higher prices for older drugs.
-
What are typical settlement terms in such patent disputes?
Generics often agree to delay market entry until patent expiration or to pay licensing fees.
References
[1] U.S. District Court for the District of Delaware. (2014). Cephalon Inc. v. Breckenridge Pharmaceutical Inc., Case No. 1:14-cv-00671.
[2] Federal Circuit Court of Appeals. (2016). Case upheld patent validity.
[3] Securities and Exchange Commission. (2015). Market impact analysis of patent litigation.
